Quotables
"There is no likelihood man can ever tap the power of the atom."
Robert Millikan, Nobel Prize winner in physics
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8088968 | Transgenic animals for analyzing CYP3A4 cytochrome P450 gene regulation The invention relates to the generation of non-human transgenic animals comprising a reporter construct for producing a detectable amount of a reporter molecule operably linked to a transcriptional regulatory nucleic acid molecule from the human CYP3A4 gene located ... | 01/03/2012 |
| 8071838 | Targeted and regional cellular ablation in zebrafish A system including: (i) a methodology for targeted cellular ablation in zebrafish; (ii) a methodology for regional cellular ablation in zebrafish. These methodologies are used to identify genetic components that regulate cellular regeneration and to identify drug co... | 12/06/2011 |
| 8067664 | PRO224 gene disruptions, and methods related thereto The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO224, PRO9783, PRO1108, PRO34000, PRO... | 11/29/2011 |
| 8058502 | Increasing lifespan by modulation of WWP-1 and UBC-18 Ubiquitin ligase wwp-1 and ubiquitin conjugating enzyme ubc-18 are identified in nematodes as mediators of dietary restriction induced longevity and therefore as targets for modulation of lifespan in animals. Methods of screening for compounds that modulate longevit... | 11/15/2011 |
| 8053627 | Methods for treating demyelination disorders This invention is in the field of neurology. Specifically, the invention relates to the discovery and characterization of molecular components that play a role in neuronal demyelination or remyelination. In addition, the invention relates to the generation of an ani... | 11/08/2011 |
| 8044259 | Determining the capability of a test compound to affect solid tumor stem cells A small percentage of cells within an established solid tumor have the properties of stem cells. These solid tumor stem cells give rise both to more tumor stem cells and to the majority of cells in the tumor that have lost the capacity for extensive proliferation an... | 10/25/2011 |
| 7989675 | Method of identifying compounds using a transgenic pig model of cystic fibrosis The present invention provides transgenic, large non-human animal models of diseases and conditions, as well as methods of using such animal models in the identification and characterization of therapies for the diseases and conditions. ... | 08/02/2011 |
| 7960605 | Methods for testing for caloric restriction (CR) mimetics Methods for treating neurological diseases and for testing Caloric Restriction (CR) mimetics or CR mimetic candidates. In one exemplary method, a CR mimetic candidate is administered to a transgenic animal and the effects of the administering are determined; the tra... | 06/14/2011 |
| 7956237 | Gene disruptions, compositions and methods relating thereto The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO196, PRO217, PRO231, PRO236, PRO245,... | 06/07/2011 |
| 7947866 | Gene disruptions, compositions and methods relating thereto The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO194, PRO220, PRO241, PRO284, PRO331,... | 05/24/2011 |
| 7928284 | Methods and animal model for analyzing age-related macular degeneration Methods for testing candidate drugs for treatment of age-related macular degeneration are provided. Ccl2-deficient, and Ccr2-deficient mice are used to determine the effect of candidate drugs and treatments on development of age-related macular degeneration. Also pr... | 04/19/2011 |
| 7928283 | Transgenic reporter system that reveals expression profiles and regulation mechanisms of alternative splicing in nematodes An object of the present invention is to develop a new alternative splicing reporter system and to provide a method for detecting alternative splicing patterns in a multicellular organism more precisely, a method for identifying efficiently substances and gene regio... | 04/19/2011 |
| 7919671 | Method for testing a compound for a therapeutic effect and a diagnostic method A method for testing compound for a therapeutic effect utilizing a non-human animal or cell having disruption in the prostatic acid phosphatase gene resulting in a decrease or absence in the activity or the level of prostatic acid phosphatase. The compound may be us... | 04/05/2011 |
| 7919670 | Transgenic mice over-expressing receptor for advanced glycation endproduct (RAGE) in brain and uses thereof The present invention provides for a transgenic non-human animal whose cells contain a DNA sequence comprising: (a) a nerve tissue specific promoter; and (b) a DNA sequence which encodes a receptor for advanced glycation endproducts (RAGE), wherein the promoter and ... | 04/05/2011 |
| 7906701 | p300 transgenic animal The present invention relates to a transgenic animal wherein DNA encoding p300 and a promoter exerting its activity in myocardial cells are introduced, and a screening method using the same. ... | 03/15/2011 |
| 7884260 | Cell-based screen for agents useful for reducing neuronal demyelination or promoting neuronal remyelination This invention is in the field of neurology. Specifically, the invention relates to the discovery and characterization of molecular components that play a role in neuronal demyelination or remyelination. In addition, the invention relates to the generation of an ani... | 02/08/2011 |
| 7858843 | Gene disruptions, compositions and methods relating thereto The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO69122, PRO204, PRO214, PRO222, PRO23... | 12/28/2010 |
| 7847146 | Model for neurodegenerative disorders The present invention discloses a double transgenic fly that expresses both Tau protein and the human Aβ42 peptide of human amyloid-β precursor protein (APP). The double transgenic flies of the present invention display a synergistic altered phenotype as compared ... | 12/07/2010 |
| 7838726 | Methods for introducing heterologous cells into fish The invention provides methods of introducing heterologous cells into fish. After introduction cells remain viable, and in some instances proliferate, for sufficient time to conduct a variety of analyses on the heterologous cells or the fish or both. Such methods ar... | 11/23/2010 |
| 7829757 | SGRF gene-modified mouse A targeting vector was constructed by replacing exon regions in the SGRF gene with appropriate drug marker genes. This vector was transfected into mouse ES cell lines to obtain chimeric mice, which were then crossed with C57BL/6J mice to obtain mice comprising cells... | 11/09/2010 |
| 7781643 | Transgenic non-human animals for pharmacological and toxicological studies The present invention is directed to the production, breeding and use of transgenic non-human animals such as mice in which specific genes or portions of genes have been replaced by homologues from another animal to make the physiology of the animals so modified mor... | 08/24/2010 |
| 7781642 | Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeri... | 08/24/2010 |
| 7772458 | Animal model for chronic obstructive pulmonary disease and cystic fibrosis A nonhuman transgenic mammal is described whose genome comprises a promoter construct operably linked to a heterologous DNA encoding an epithelial sodium channel β subunit, wherein said promoter construct directs expression of the epithelial sodium channel β subun... | 08/10/2010 |
| 7754941 | Animal models for demyelination disorders This invention is in the field of neurology. Specifically, the invention relates to the discovery and characterization of molecular components that play a role in neuronal demyelination or remyelination. In addition, the invention relates to the generation of an ani... | 07/13/2010 |
| 7723562 | Mice lacking alpha 1G showing enhanced novelty-seeking and alcohol preference and therapeutic methods for mood disorders by modulating alpha 1G T-type calcium channels The present invention relates to a novel use of an α1G T-type calcium channel transgenic mouse as a nervous disease model, more particularly, a novel use of a mouse deficient in α1G T-type calcium channel showing novelty-seeking and alcohol preference as a nervous... | 05/25/2010 |
| 7705196 | sFRP expression enhancing agent Tumor formation and reduced transcription of both sFRP1 gene and sFRP2 gene were found in Dlg gene knock-out mice, and thereby the following has been provided: an agent for enhancing the expression and/or function of sFRP, containing a compound having an effect of e... | 04/27/2010 |
| 7705197 | Embryo development and survival An embryo that is transferred into the uterus of a recipient female is protected from embryotoxic effects of prostaglandin F2α by exposing the embryo to a prostaglandin antagonist. ... | 04/27/2010 |
| 7705195 | Screening method The present invention is directed to methods using transgenic mice to screen for biologically active agents. ... | 04/27/2010 |
| 7700822 | Modulation of cytochrome P450 reductase activity The present invention relates to non-human transgenic animals, tissues and/or cells derived therefrom having depleted or ablated cytochrome P450 reductase (CPR) expression, methods of producing such animals, tissues and/or cells, and methods of using such animals, t... | 04/20/2010 |
| 7696403 | Nonhuman model animal of Th2-mediated hyperimmune response An object of the present invention is to provide a nonhuman model animal of Th2-mediated hyperimmune response lacking PIR-B gene function on its chromosome by which the Th2-mediated immune response mechanism and allergy onset mechanism in vivo can be analyzed and wh... | 04/13/2010 |
| 7655832 | Rapid-throughput teleost regeneration assay The present invention provides a method of simultaneously screening at least two candidate agents for an activity affecting regeneration of an embryonic teleost. According to this method, for each agent, a fin of the embryonic teleost is amputated. Next, the amputat... | 02/02/2010 |
| 7626074 | Method of screening candidate drugs for the treatment of leukemia Transgenic non-human mammals that reproduce human pathologies of stem cell origins, such as chromosomal anomalies associated with chronic myeloid leukemia, B-cell acute lymphoblastic leukemia, T-cell acute or lymphoblastic leukemia, or with the migration of hematopo... | 12/01/2009 |
| 7615676 | Transgenic screen and method for screening modulators of brain-derived neurotrophic factor (BDNF) production A transgenic screen and method for screening biological and chemical test substances or molecules for their ability to influence or modulate the production of BDNF in cells, includes a fusion gene having a zebrafish BDNF gene fragment (promoter) and a fluorescent ma... | 11/10/2009 |
| 7601883 | Mammalian sour/acid taste and CSF receptor genes, polypeptides and assays Acid/sour taste receptors are provided. CSF pH sensing receptors are provided. Methods and systems for screening for tastants and receptor modulators are provided. Knock out and transgenic animals, antibodies to the receptors, methods of detecting polymorphisms, and... | 10/13/2009 |
| 7595431 | Mouse models of human prostate cancer The present invention provides an immune deficient mouse having a human prostate xenograft of locally advanced or metastatic prostate cancer and uses thereof. ... | 09/29/2009 |
| 7595430 | Methods and animal model for analyzing age-related macular degeneration Methods for testing candidate drugs for treatment of age-related macular degeneration are provided. Ccl2-deficient, and Ccr2-deficient mice are used to determine the effect of candidate drugs and treatments on development of age-related macular degeneration. Also pr... | 09/29/2009 |
| 7592501 | Methods for maintaining genetic stability of inbred animal strains The present invention provides novel methods of maintaining genetic stability of non-human animal inbred strains. In the methods, pedigree-tracked cryopreserved embryos derived from a foundation colony are produced and used to re-establish the foundation colony at a... | 09/22/2009 |
| 7531712 | P450 gene regulation The invention relates to the generation of non-human transgenic animals comprising a reporter construct for producing a detectable amount of a reporter molecule operably linked to a transcriptional regulatory nucleic acid molecule from the human CYP3A4 gene located ... | 05/12/2009 |
| 7531713 | Assay for toxin induced neuronal degeneration and viability in Provided are in vivo screening methods to detect and identify substances that affect neuronal viability, and/or prevent neurodegeneration, and/or confer neuroprotective effects The screening methods utilize recombinant C. elegans expressing a detectable marke... | 05/12/2009 |
| 7504554 | Animal model for identifying agents that inhibit or enhance CTLA4 signaling The present invention relates to a non-human transgenic animal, particularly a knock in mouse, whose genome comprises a heterologous, chimeric CTLA4 gene. The chimeric CTLA4 gene comprises exon 2 of the human CTLA4 gene, exon 1 and exon 4 of the non-human animal, an... | 03/17/2009 |
